The primary goal of this project is to use differences in the human response to a single vaccine antigen to determine factors that are critical to the ability of an individual to make a protective response to the vaccine. The vaccine antigen used in these studies is the major surface antigen of Hepatitis B virus, HBsAg. Using a broad range of tools, including genome-wide transcriptional profiling, multiparameter flow cytometry and detailed functional phenotyping of antigen-specific T cell subset, we will determine which components of the innate and adaptive response to vaccine correlate best with the seroprotective response to vaccination. The major part of this project will be a systems biology study of the same antigen, HBsAg, with two different adjuvants. Alum and the Toll-like receptor-9 agonist, CpG-ODN. Clinical trials have shown CpG-ODN to be a much more effective vaccine, especially in subjects that respond poorly to vaccination due age or disease. We propose to compare transcriptional and cellular responses to these two adjuvants in older healthy adults and later in patients with end-stage renal disease of HIV infection. This study presents a unique opportunity to study in humans the mechanisms of action of the most widely used adjuvant, alum and one of the most promising modern adjuvant candidates, CpG-ODN, in a study in which the adjuvants are the only significant variable. These studies will constitute an important advance in our understanding of the actions of adjuvants and will hopefully identify the primary reasons for unresponsiveness to vaccination in older adults and in specific disease states.
Many adults respond poorly to vaccination because of old age or disease. As a result, many of the people most in need of vaccination are not effectively protected. New vaccine adjuvants offer promise for improving results in these difficult to immunize groups, but the way they work is not understood. The goal of this project is to provide a clear understanding of how vaccine adjuvants work in poorly responding individuals and to suggest new strategies to develop improved vaccines for these groups.
|Yu, Chun I; Becker, Christian; Metang, Patrick et al. (2014) Human CD141+ dendritic cells induce CD4+ T cells to produce type 2 cytokines. J Immunol 193:4335-43|
|Banchereau, Romain; Baldwin, Nicole; Cepika, Alma-Martina et al. (2014) Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. Nat Commun 5:5283|
|Chaussabel, Damien; Baldwin, Nicole (2014) Democratizing systems immunology with modular transcriptional repertoire analyses. Nat Rev Immunol 14:271-80|
|Rajsbaum, Ricardo; Garcia-Sastre, Adolfo; Versteeg, Gijs A (2014) TRIMmunity: the roles of the TRIM E3-ubiquitin ligase family in innate antiviral immunity. J Mol Biol 426:1265-84|
|Cao, Raquel G; Suarez, Nicolas M; Obermoser, Gerlinde et al. (2014) Differences in antibody responses between trivalent inactivated influenza vaccine and live attenuated influenza vaccine correlate with the kinetics and magnitude of interferon signaling in children. J Infect Dis 210:224-33|
|Schotsaert, Michael; García-Sastre, Adolfo (2014) Influenza vaccines: a moving interdisciplinary field. Viruses 6:3809-26|
|Alsina, Laia; Israelsson, Elisabeth; Altman, Matthew C et al. (2014) A narrow repertoire of transcriptional modules responsive to pyogenic bacteria is impaired in patients carrying loss-of-function mutations in MYD88 or IRAK4. Nat Immunol 15:1134-42|
|Ovsyannikova, Inna G; White, Sarah J; Albrecht, Randy A et al. (2014) Turkey versus guinea pig red blood cells: hemagglutination differences alter hemagglutination inhibition responses against influenza A/H1N1. Viral Immunol 27:174-8|
|Li, Lily; Lin, Marvin; Krassilnikova, Maria et al. (2014) Effect of cholecalciferol supplementation on inflammation and cellular alloimmunity in hemodialysis patients: data from a randomized controlled pilot trial. PLoS One 9:e109998|
|Tsang, John S; Schwartzberg, Pamela L; Kotliarov, Yuri et al. (2014) Global analyses of human immune variation reveal baseline predictors of postvaccination responses. Cell 157:499-513|
Showing the most recent 10 out of 33 publications